Dolores Isla

13PUBLICATIONS
73CO-AUTHORS
Predictive and prognostic markersLiquid biopsiesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 28, 2026
Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1.

|Mar 01, 2026
Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial).

Aida Piedra, Albert Guinart-Cuadra, Sergio Martínez-Recio

|Jun 19, 2025
Recommendations for diagnosis and management of non-small-cell lung carcinoma patients with ex20ins EGFR mutations: insights from a Delphi consensus.

Dolores Isla, Esther Conde, Atocha Romero

|Oct 10, 2024
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis.

Dolores Isla, Rosa Álvarez, María Arnal

|Apr 17, 2024
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.

Melina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti

|Aug 12, 2023
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement.

Dolores Isla, Alfredo Sánchez, Joaquín Casal

Pageof 3

Frequent Collaborators

5 joint publications

Margarita Majem

4 joint publications

Edurne Arriola

3 joint publications

Alberto Moreno-Vega

3 joint publications

Manuel Cobo